相似文献
1
Antithrombotic therapy after coronary artery stenting in atrial fibrillation: dual therapy encompassing NOAC plus P2Y12 inhibitor is ready for prime time!
Ann Transl Med. 2019 Dec;7(Suppl 8):S270. doi: 10.21037/atm.2019.12.33.
2
Antithrombotic Strategies in Patients with Atrial Fibrillation Following Percutaneous Coronary Intervention: A Systemic Review and Network Meta-Analysis of Randomized Controlled Trials.
J Clin Med. 2020 Apr 8;9(4):1062. doi: 10.3390/jcm9041062.
3
Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Curr Treat Options Cardiovasc Med. 2019 Feb 7;21(1):3. doi: 10.1007/s11936-019-0705-8.
4
High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.
J Thromb Thrombolysis. 2016 Nov;42(4):558-65. doi: 10.1007/s11239-016-1397-5.
5
Triple vs Dual Antithrombotic Therapy in Patients with Atrial Fibrillation and Coronary Artery Disease.
Am J Med. 2016 Jun;129(6):592-599.e1. doi: 10.1016/j.amjmed.2015.12.026. Epub 2016 Jan 18.
6
Clinical Outcomes of Antithrombotic Strategies for Patients with Atrial Fibrillation After Percutaneous Coronary Intervention.
Int Heart J. 2019 May 30;60(3):546-553. doi: 10.1536/ihj.18-464. Epub 2019 May 17.
7
Triple Antithrombotic Therapy for Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention.
Prog Cardiovasc Dis. 2018 Jan-Feb;60(4-5):524-530. doi: 10.1016/j.pcad.2018.01.008. Epub 2018 Feb 3.
8
Contemporary Antithrombotic Treatment in Patients with Non-valvular Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: Rationale and Design of the Greek AntiPlatElet Atrial Fibrillation (GRAPE-AF) Registry.
Cardiovasc Drugs Ther. 2018 Apr;32(2):191-196. doi: 10.1007/s10557-018-6789-7.
9
Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
J Cardiol. 2017 Apr;69(4):648-651. doi: 10.1016/j.jjcc.2016.06.007. Epub 2016 Jul 18.
10
Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting.
J Cardiol. 2015 Mar;65(3):197-202. doi: 10.1016/j.jjcc.2014.08.013. Epub 2014 Sep 26.
引用本文的文献
1
Atrial cardiomyopathy revisited-evolution of a concept: a clinical consensus statement of the European Heart Rhythm Association (EHRA) of the ESC, the Heart Rhythm Society (HRS), the Asian Pacific Heart Rhythm Society (APHRS), and the Latin American Heart Rhythm Society (LAHRS).
Europace. 2024 Aug 30;26(9). doi: 10.1093/europace/euae204.
2
Safety and efficacy of double vs. triple antithrombotic therapy in patients with atrial fibrillation with or without acute coronary syndrome undergoing percutaneous coronary intervention: a collaborative meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Eur Heart J Cardiovasc Pharmacother. 2021 Apr 9;7(FI1):f50-f60. doi: 10.1093/ehjcvp/pvaa116.
3
Platelet microRNA-15b protects against high platelet reactivity in patients undergoing percutaneous coronary intervention through Bcl-2-mediated platelet apoptosis.
Ann Transl Med. 2020 Mar;8(6):364. doi: 10.21037/atm.2020.02.88.
本文引用的文献
1
Stent Thrombosis in Patients With Atrial Fibrillation Undergoing Coronary Stenting in the AUGUSTUS Trial.
Circulation. 2020 Mar 3;141(9):781-783. doi: 10.1161/CIRCULATIONAHA.119.044584. Epub 2019 Nov 11.
2
Safety and efficacy outcomes of double vs. triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials.
Eur Heart J. 2019 Dec 7;40(46):3757-3767. doi: 10.1093/eurheartj/ehz732.
3
Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial.
Lancet. 2019 Oct 12;394(10206):1335-1343. doi: 10.1016/S0140-6736(19)31872-0. Epub 2019 Sep 3.
4
Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis.
Europace. 2019 Nov 1;21(11):1633-1638. doi: 10.1093/europace/euz213.
5
Safety and Efficacy of Antithrombotic Strategies in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A Network Meta-analysis of Randomized Controlled Trials.
JAMA Cardiol. 2019 Aug 1;4(8):747-755. doi: 10.1001/jamacardio.2019.1880.
6
Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.
N Engl J Med. 2019 Apr 18;380(16):1509-1524. doi: 10.1056/NEJMoa1817083. Epub 2019 Mar 17.
7
Evaluation of the safety and efficacy of an edoxaban-based antithrombotic regimen in patients with atrial fibrillation following successful percutaneous coronary intervention (PCI) with stent placement: Rationale and design of the ENTRUST-AF PCI trial.
Am Heart J. 2018 Feb;196:105-112. doi: 10.1016/j.ahj.2017.10.009. Epub 2017 Oct 23.
8
Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.
N Engl J Med. 2017 Oct 19;377(16):1513-1524. doi: 10.1056/NEJMoa1708454. Epub 2017 Aug 27.
9
Prevention of Bleeding in Patients with Atrial Fibrillation Undergoing PCI.
N Engl J Med. 2016 Dec 22;375(25):2423-2434. doi: 10.1056/NEJMoa1611594. Epub 2016 Nov 14.
10
EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: definition, characterization, and clinical implication.
Europace. 2016 Oct;18(10):1455-1490. doi: 10.1093/europace/euw161. Epub 2016 Jul 8.
Zotero 插件